 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...165166167168169170171172173174175...235236» |
- leucovorin calcium / generics
Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2706;
Legal entity responsible for the study: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Funding: The National Research Council of Thailand and Siriraj foundation, Siriraj Hospital.
- Tecentriq (atezolizumab) / Roche
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2486;
P2
Legal entity responsible for the study: IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest. Funding: F. Hoffmann-La Roche Ltd.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2480;
P2
Legal entity responsible for the study: IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest. Funding: Bristol-Myers Squibb.
- Tedopi (OSE 2101) / OSE Immunotherapeutics, Opdivo (nivolumab) / Ono Pharma, BMS
A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2475;
P2
Legal entity responsible for the study: GERCOR. Funding: OSE Immunotherapeutics.
- Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda
Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2474;
P2
Legal entity responsible for the study: The authors. Funding: Shire and Servier.
- irinotecan / generics
Simultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2473;
P3
Legal entity responsible for the study: The Chinese Study Group for Pancreatic Cancer (CSPAC), Shanghai Shenkang Hospital Development Center, BeiGene Pharmaceutical Co., Ltd. Funding: The Chinese Study Group for Pancreatic Cancer (CSPAC), Shanghai Shenkang Hospital Development Center, BeiGene Pharmaceutical Co., Ltd.
- Perioperative chemotherapy with docetaxel, oxaliplatin, fluorouracil and leucovorin (FLOT) versus epirubicin, platinum and capecitabine or flourouracil (EOX/ECF) in resectable gastric or gastroesophageal junction adenocarcinoma: Safety and response data from India (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2428;
The patients in both groups are currently on follow up to capture the relapse free survival duration. Legal entity responsible for the study: Tanuj Chawla.
- leucovorin calcium / generics, irinotecan / generics
FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2361;
Legal entity responsible for the study: Besançon University Hospital. Funding: Has not received any funding.
- Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda
Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2336;
P1/2
The results suggest that UGT status has no impact on the PK of nal-IRI. Legal entity responsible for the study: Ipsen.
- irinotecan / generics, gemcitabine / generics
Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2334;
P2
Clinical trial identification: NCT02749136. Legal entity responsible for the study: The authors.
- onvansertib (PCM-075) / TrovaGene, Avastin (bevacizumab) / Roche
A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer in patients with a KRAS mutation (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2323;
P1b/2
Legal entity responsible for the study: Trovagene. Funding: Trovagene.
- Avastin (bevacizumab) / Roche, Modufolin (arfolitixorin) / Isofol Medical
Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2320;
P3
Legal entity responsible for the study: Isofol Medical AB. Funding: Isofol Medical AB.
- Avastin (bevacizumab) / Roche
Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2308;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- leucovorin calcium / generics, irinotecan / generics
Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2301;
There are no obvious reasons for the lack of prediction before 2000 but options include mRNA degradation, change in handling of samples, or the selection of older patients after 2000. [1] PLOS ONE; 11(5): e0155123.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2265;
P1b
Clinical trial identification: NCT03374254; Release date: December 15, 2017. Legal entity responsible for the study: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Array BioPharma.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Mismatch repair, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Sep 11, 2019
P3, N=308, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Legal entity responsible for the study: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Array BioPharma. Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Dec 2021
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: CELIM2: Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases (clinicaltrials.gov) - Sep 11, 2019
P2, N=91, Active, not recruiting, Sponsor: Technische Universit
Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Dec 2021 Recruiting --> Active, not recruiting | N=256 --> 91 | Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2017 --> Sep 2019
- | leucovorin calcium / generics
Journal: A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis. (Pubmed Central) - Sep 11, 2019
...The generic therapy for toxoplasmosis has been a combination of antifolates such as pyrimethamine or trimethoprim with either sulfadiazine or antibiotics such as clindamycin with a combination with leucovorin to prevent hematologic toxicity...Thiazolidinone derivatives have been reportedly as building blocks in organic chemistry and as scaffolds for drug discovery. Here we present a perspective of how structural modifications of the thiazolidinone core could generate new compounds with high anti-parasitic effect and less toxic results.
- | leucovorin calcium / generics, methotrexate / generics
Preclinical, Journal: Modified enzyme multiplied immunoassay technique of methotrexate assay to improve sensitivity and reduce cost. (Pubmed Central) - Sep 11, 2019
In addition, the test number of a reagent Kit increased from 140 to 210. This means the cost of detection was reduced about 30%.
- | leucovorin calcium / generics, fluorouracil / generics
Biomarker, Clinical, Journal: Plasma exosomal microRNA-125b as a monitoring biomarker of resistance to mFOLFOX6-based chemotherapy in advanced and recurrent colorectal cancer patients. (Pubmed Central) - Sep 10, 2019
The present results suggest that plasma ex-miR-125b levels may be useful for the early detection of resistance to mFOLFOX6-based first-line chemotherapy. Furthermore, ex-miR-125b before chemotherapy is a predictive biomarker for PFS in patients with advanced/recurrent CRC.
- leucovorin calcium / Generic mfg.
CERVICAL ECTOPIC PREGNANCY IN A PATIENT SUSPECTED WITH CERVICAL CANCER: A CASE REPORT (E-Poster Area (Americas)) - Sep 10, 2019 - Abstract #IGCS2019IGCS_344;
The low incidence of cervical pregnancy in contrary with cervical carcinoma’s incidence in Bali becomes a major obstacle in diagnosing and in the provision of therapy. An accurate history, physical examination and pregnancy test are key modalities in the determination of cervical pregnancy, supported by histopathologic examination, TVS ultrasound examination and MRI.
- | leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial completion: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 10, 2019
P3, N=3154, Completed, Sponsor: Children's Oncology Group
An accurate history, physical examination and pregnancy test are key modalities in the determination of cervical pregnancy, supported by histopathologic examination, TVS ultrasound examination and MRI. Active, not recruiting --> Completed
- | Opdivo (nivolumab) / BMS
Enrollment open: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Sep 9, 2019
P4, N=1200, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P3 trial, Metastases: NAPOLI-3: A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (clinicaltrials.gov) - Sep 9, 2019
P3, N=750, Not yet recruiting, Sponsor: Ipsen
- leucovorin calcium / generics, fluorouracil / generics
Medical Therapy Optimization of Advanced Heart Failure in a Cancer Patient: When to Quit? () - Sep 9, 2019 - Abstract #HFSA2019HFSA_316;
Medical therapy optimization in all patients with CHF should always be sought. Despite being challenging under certain circumstances, as seen in our patient, slow and cautious MTO can eventually result in significant improvement in clinical status, cardiac function, and candidacy for other therapy options for other comorbidities.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche
Clinical, Journal: The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer. (Pubmed Central) - Sep 8, 2019
We reported the case of a patient affected by metastatic colorectal adenocarcinoma RAS/ BRAF wild-type, with an initial liver-limited presentation. In this case we used a second line treatment with FOLFIRI aflibercept after a first-line oxaliplatin-based chemotherapy plus an anti-EGFR antibody.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Preclinical, Journal: Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. (Pubmed Central) - Sep 8, 2019
In this case we used a second line treatment with FOLFIRI aflibercept after a first-line oxaliplatin-based chemotherapy plus an anti-EGFR antibody. Our study contributes to deciphering the molecular mechanisms of acquired resistance to cetuximab.
- | leucovorin calcium / generics
Journal: Anti-platelet aggregation mechanism of Xixian Tongshuan Preparation based on molecular simulation methods (Pubmed Central) - Sep 7, 2019
The screening results indicated that the anti-platelet aggregation effect of Xixian Tongshuan Preparation was correlated with the inhibition of P2 Y12,PAR1 and GPⅡb/Ⅲa expressions with saffower yellower,hirudin and candidin and notoginseng triterpenes,folinic acid,respectively. The material basis and mechanism of anti-platelet aggregation of Xixian Tongshuan Preparation provided a theoretical basis for the clinical use of the preparation and the lead compounds for the development of anti-platelet aggregation drugs.
- | Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda
Clinical, Journal, Real-World Evidence: Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. (Pubmed Central) - Sep 7, 2019
Most common grade 3-4 toxicities were neutropenia (37.2%), nausea (10.5%), vomiting (9.3%), anorexia (8.1%) and diarrhoea (4.7%). Real-life data for Korean patients indicate that, consistent with NAPOLI-1, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with mPAC that progressed on gemcitabine-based therapy.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Biomarker, Clinical, P3 data, Journal: Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. (Pubmed Central) - Sep 6, 2019
Real-life data for Korean patients indicate that, consistent with NAPOLI-1, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with mPAC that progressed on gemcitabine-based therapy. Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Sep 6, 2019
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Trial primary completion date: Aug 2019 --> Aug 2020
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2019
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2019
P2, N=53, Suspended, Sponsor: Children's Oncology Group
Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Sep 6, 2019
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Sep 2020
- | Opdivo (nivolumab) / BMS
Enrollment closed: CheckMate 9X8: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (clinicaltrials.gov) - Sep 5, 2019
P2/3, N=180, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Sep 2020 Recruiting --> Active, not recruiting
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Metastases: NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) - Sep 5, 2019
P2, N=44, Recruiting, Sponsor: Georgetown University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS
Enrollment open: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Sep 5, 2019
P1/2, N=36, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Successful treatment of unresectable advanced gastric cancer with bladder metastasis using mFOLFOX6:a case report (Pubmed Central) - Sep 5, 2019
After changing the regimen to tegafur/gimeracil/oteracil and oxaliplatin, she was discharged. Currently, she continues to receive chemotherapy.
- | Ukoniq (umbralisib) / TG Therap
Trial completion, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Sep 4, 2019
P1, N=66, Completed, Sponsor: TG Therapeutics, Inc.
Currently, she continues to receive chemotherapy. Active, not recruiting --> Completed
- | Enrollment open, PD(L)-1 Biomarker: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Sep 3, 2019
P1, N=52, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Clinical, Journal: Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial. (Pubmed Central) - Aug 30, 2019
P2
The GEMCAD 1402 trial provides a rationale for phase 3 trials. ClinicalTrials.gov identifier: NCT02340949.
- | leucovorin calcium / generics
Clinical, Journal: Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer. (Pubmed Central) - Aug 30, 2019
The results indicate the possibility of using the individual plasma 5-MTHF/LV ratio after LV injection as a surrogate marker for tissue folate concentration. Expression of several folate-associated genes is associated with folate concentration in tissue and plasma and may become useful when predicting response to LV treatment.
- | Ziihera (zanidatamab-hrii) / Jazz
Trial completion date, Trial primary completion date: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Aug 29, 2019
P2, N=115, Recruiting, Sponsor: Zymeworks Inc.
Expression of several folate-associated genes is associated with folate concentration in tissue and plasma and may become useful when predicting response to LV treatment. Trial completion date: Oct 2023 --> Jan 2023 | Trial primary completion date: Oct 2021 --> Feb 2022
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche
Clinical, Journal: Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. (Pubmed Central) - Aug 29, 2019
Six-months survivals were 65% in arm A and 80% in arm B. Folfiri/bevacizumab and folfiri/aflibercept are equally effective second-line therapies in RAS-M mCRC patients. Although not significant, folfiri/aflibercept was associated with a lower risk of death particularly during the 6-months induction phase.
- | locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
Trial completion date, Trial primary completion date: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 29, 2019
P1/2, N=150, Recruiting, Sponsor: Tarveda Therapeutics
Although not significant, folfiri/aflibercept was associated with a lower risk of death particularly during the 6-months induction phase. Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Dec 2019 --> Dec 2021
- | Enrollment change, Trial withdrawal: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Aug 29, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
Trial completion date: Jun 2020 --> Jun 2022 | Trial primary completion date: Dec 2019 --> Dec 2021 N=79 --> 0 | Not yet recruiting --> Withdrawn
- | ipatasertib (RG7440) / Roche
Trial completion date, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 28, 2019
P2, N=154, Active, not recruiting, Sponsor: Genentech, Inc.
N=79 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2019 --> Dec 2020
- | Folotyn (pralatrexate) / Aurobindo
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 28, 2019
P2, N=36, Completed, Sponsor: Acrotech Biopharma LLC
Trial completion date: Jun 2019 --> Dec 2020 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jun 2019 | Trial primary completion date: Nov 2019 --> Oct 2018
- | Trial completion date, Trial primary completion date, Combination therapy: Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI (clinicaltrials.gov) - Aug 28, 2019
P1, N=16, Recruiting, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jun 2019 | Trial primary completion date: Nov 2019 --> Oct 2018 Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Aug 2020
- | Enrollment change, Trial withdrawal: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Aug 2020 N=113 --> 0 | Not yet recruiting --> Withdrawn